Study of tarlatamab and AB248 for extensive stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have extensive stage small cell lung cancer that has gotten worse after at least one prior treatment.
- You have at least one tumor that can be measured on a scan, and it has not been treated with radiation.
- Your organs (like heart, lungs, kidneys, and liver) are working well enough for the study.
- You are able to provide a fresh or stored tumor sample taken after your last cancer treatment.
- You do not need oxygen at rest and do not have certain types of untreated brain metastases or have had prior treatments with specific drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
This trial tests a new drug called tarlatamab, given as an injection under the skin (like a shot), for people with advanced small cell lung cancer that has worsened after chemotherapy. The goal is to see if this treatment can help shrink or slow down the cancer.
This trial tests a combination of two drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after one prior treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.